Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 29, 2020 - Issue 7
Submit an article Journal homepage
270
Views
13
CrossRef citations to date
0
Altmetric
Drug Evaluation

Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration

Lorenzo Ferro Desideria IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genoa, ItalyCorrespondence[email protected]
View further author information
,
Carlo Enrico Traversob Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (Dinogmi), University of Genoa, Genoa, Italy;a IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genoa, ItalyView further author information
&
Massimo Nicolòc Macula Onlus Foundation, Genoa, Italy;b Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (Dinogmi), University of Genoa, Genoa, Italy;a IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genoa, ItalyView further author information
Pages 651-658 | Received 30 Mar 2020, Accepted 19 May 2020, Published online: 01 Jun 2020

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Lorenzo Ferro Desideri, Carlo Enrico Traverso & Massimo Nicolò. (2022) The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases. Expert Opinion on Therapeutic Targets 26:2, pages 145-154.
Read now
Stephanie M Kaiser, Sruthi Arepalli & Justis P Ehlers. (2021) Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. Journal of Experimental Pharmacology 13, pages 905-912.
Read now
Alessandro Arrigo & Francesco Bandello. (2021) Retinal vein occlusion: drug targets and therapeutic implications. Expert Opinion on Therapeutic Targets 25:10, pages 847-864.
Read now
Vijay Chaitanya Ganta & Brian H. Annex. (2021) Peripheral vascular disease: preclinical models and emerging therapeutic targeting of the vascular endothelial growth factor ligand-receptor system. Expert Opinion on Therapeutic Targets 25:5, pages 381-391.
Read now

Articles from other publishers (9)

Lu Teng, Yabin Sun, Siying Teng & Peng Hui. (2023) Applications of nanomaterials in anti‐VEGF treatment for ophthalmic diseases . Journal of Biomedical Materials Research Part A 112:2, pages 296-306.
Crossref
Xi Huang, Li Zhang, Yanyan Fu, Meixia Zhang, Qian Yang & Jinrong Peng. (2023) Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy. Frontiers in Bioengineering and Biotechnology 11.
Crossref
Lorenzo Ferro Desideri, Carlo Enrico Traverso, Massimo Nicolò & Marion R. Munk. (2023) Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. Pharmaceutics 15:5, pages 1413.
Crossref
Divyesh H. Shastri, Ana Catarina Silva & Hugo Almeida. (2023) Ocular Delivery of Therapeutic Proteins: A Review. Pharmaceutics 15:1, pages 205.
Crossref
Peter K. Kaiser, Andrea Giani, Holger Fuchs, Victor Chong & Jeffery S. Heier. (2023) Factors That Can Prolong Ocular Treatment Duration in Age-Related Macular Degeneration. Ophthalmic Research, pages 653-663.
Crossref
Juan Wu, Dongmei Cui, honghui li & Junwen Zeng. (2021) Protective effects of NAC and salubrinal on apoptosis of retinal pigment epithelial cells induced by all-trans retinoic acid. European Journal of Ophthalmology 32:1, pages 395-401.
Crossref
Dionysis D. Balatsoukas, Konstantinos T. Tsaousis, Konstadinos G. Boboridis, Anastasios G. Konstas & Fotis Topouzis. (2021) Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview. Advances in Therapy 39:1, pages 5-32.
Crossref
M. V. Budzinskaya & A. A. Plyukhova. (2021) Future Perspectives for Antiangiogenic Therapy in Retinal Diseases. Ophthalmology in Russia 18:3S, pages 638-645.
Crossref
Massimo Nicolò, Lorenzo Ferro Desideri, Aldo Vagge & Carlo Enrico Traverso. (2020) Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review. Pharmaceuticals 13:10, pages 264.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.